A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.

HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 ... DPP4 inhibitors, and SGLT2 inhibitors (536,068 people), as well as a control group that ...

HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists ... SGLT2 inhibitors (536,068 people), as well as a control group that continued use of non-GLP ...

Study of 2.4 million participants reveals potential advantages for cardiometabolic and psychiatric conditions alongside increased risks of gastrointestinal and musculoskeletal issues Study ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...